Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 2
2002 1
2003 2
2004 3
2005 4
2006 6
2007 2
2008 1
2009 4
2010 7
2011 5
2012 10
2013 4
2014 5
2015 6
2016 6
2017 13
2018 5
2019 3
2021 5
2022 1
2023 4
2024 3
2025 6
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Citations

3 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Management of Menopausal Symptoms: A Review.
Crandall CJ, Mehta JM, Manson JE. Crandall CJ, et al. JAMA. 2023 Feb 7;329(5):405-420. doi: 10.1001/jama.2022.24140. JAMA. 2023. PMID: 36749328 Review.
Oral and transdermal estrogen have similar efficacy. Conjugated equine estrogens (CEE) with or without medroxyprogesterone acetate (MPA) were the only hormonal treatments for which clinical trials were designed to examine cardiovascular events, venous thromboembolis …
Oral and transdermal estrogen have similar efficacy. Conjugated equine estrogens (CEE) with or without medroxyprogesterone acetate (M …
The Art of Hormone Replacement Therapy (HRT) in Menopause Management.
Cameron CR, Cohen S, Sewell K, Lee M. Cameron CR, et al. J Pharm Pract. 2024 Jun;37(3):736-740. doi: 10.1177/08971900231167925. Epub 2023 Apr 1. J Pharm Pract. 2024. PMID: 37002679 Review.
Hormone replacement therapy (HRT) is considered the gold standard for management of vasomotor and vaginal symptoms of menopause. ...These include consideration of cyclic vs continuous administration and of tapering therapy. Additionally, estrogen is av …
Hormone replacement therapy (HRT) is considered the gold standard for management of vasomotor and vaginal symptoms of menopaus …
Migraine, menopause and hormone replacement therapy.
MacGregor EA. MacGregor EA. Post Reprod Health. 2018 Mar;24(1):11-18. doi: 10.1177/2053369117731172. Epub 2017 Oct 10. Post Reprod Health. 2018. PMID: 28994639 Review.
In women with migraine with or without aura, using only the lowest doses of transdermal estrogen necessary to control vasomotor symptoms minimizes the risk of unwanted side effects. ...Non-hormonal options for both conditions are limited but there is evidence …
In women with migraine with or without aura, using only the lowest doses of transdermal estrogen necessary to control vasomotor sympt …
Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy: A Review and Contemporary Approach to Risk Assessment.
D'Costa Z, Spertus E, Hingorany S, Patil R, Horwich T, Press MC, Shah J, Watson KE, Jafari L. D'Costa Z, et al. Curr Atheroscler Rep. 2025 Oct 9;27(1):100. doi: 10.1007/s11883-025-01343-6. Curr Atheroscler Rep. 2025. PMID: 41066010 Free PMC article. Review.
PURPOSE OF REVIEW: Discuss the effects of menopause and menopause hormone therapy (MHT) on cardiovascular risk, and propose a structured, person-centered framework for cardiovascular risk assessment when initiating MHT. RECENT FINDINGS: The risk …
PURPOSE OF REVIEW: Discuss the effects of menopause and menopause hormone therapy (MHT) on cardiovascular risk, and pro …
Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
Genazzani AR, Monteleone P, Giannini A, Simoncini T. Genazzani AR, et al. Hum Reprod Update. 2021 Oct 18;27(6):1115-1150. doi: 10.1093/humupd/dmab026. Hum Reprod Update. 2021. PMID: 34432008 Free article. Clinical Trial.
Women should be made aware that there is a small increased risk of stroke that tends to persist over the years as well as breast cancer risk with long-term estrogen-progestin use. ...Where possible, transdermal routes of HT administration should …
Women should be made aware that there is a small increased risk of stroke that tends to persist over the years as well as brea …
Cardiovascular Safety of Testosterone-Replacement Therapy.
Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Study Investigators. Lincoff AM, et al. N Engl J Med. 2023 Jul 13;389(2):107-117. doi: 10.1056/NEJMoa2215025. Epub 2023 Jun 16. N Engl J Med. 2023. PMID: 37326322 Clinical Trial.
BACKGROUND: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined. METHODS: In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 ye …
BACKGROUND: The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been …
Long-term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Marjoribanks J, et al. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2025 Nov 27;11:CD004143. doi: 10.1002/14651858.CD004143.pub6. PMID: 28093732 Free PMC article. Updated.
BACKGROUND: Hormone therapy (HT) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. ...HT included oestrogens, with or without progestogens, v …
BACKGROUND: Hormone therapy (HT) is widely provided for control of menopausal symptoms and has been used for the management an …
Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
Shufelt CL, Manson JE. Shufelt CL, et al. J Clin Endocrinol Metab. 2021 Apr 23;106(5):1245-1254. doi: 10.1210/clinem/dgab042. J Clin Endocrinol Metab. 2021. PMID: 33506261 Free PMC article. Review.
CONTEXT: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk, with a focus on the role of hormone formulation, dose, and route of delivery. ...Transdermal estrogens have less effect on c …
CONTEXT: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk …
Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review.
Arnautu AM, Nimigean VR, Nacea-Radu CA, Tilici DM, Paun DL. Arnautu AM, et al. Int J Mol Sci. 2025 Nov 17;26(22):11098. doi: 10.3390/ijms262211098. Int J Mol Sci. 2025. PMID: 41303580 Free PMC article. Review.
Cardiovascular prevention is not an indication. Benefit-risk depends on timing, route, and dose. Initiation within 10 years of menopause as well as the use of transdermal estradiol at low-moderate doses are favored when cardiometabolic or thrombotic risk is s …
Cardiovascular prevention is not an indication. Benefit-risk depends on timing, route, and dose. Initiation within 10 years of menopa …
The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, Chowdhury R, Franco OH, Muka T. Oliver-Williams C, et al. Hum Reprod Update. 2019 Mar 1;25(2):257-271. doi: 10.1093/humupd/dmy039. Hum Reprod Update. 2019. PMID: 30508190 Free article.
BACKGROUND: The effect of postmenopausal hormone therapy (HT) on cardiovascular disease (CVD) risk remains controversial. OBJECTIVE AND RATIONALE: We aimed to systematically review the evidence regarding the role of dose, route of hormone administra …
BACKGROUND: The effect of postmenopausal hormone therapy (HT) on cardiovascular disease (CVD) risk remains controversia …
106 results